ERS Presidential Summits are a forum for discussion in the interface between science and policy. The 2014 Presidential Summit hosted speakers from a range of fields, from policymakers to researchers and patients, coming together to discuss key issues in medicine development. More specifically the objectives of the 2014 Summit were to examine the various barriers to new medical products, from research to regulatory issues, and explore new ways to create a better environment for medicine development.
Introduction P.J. Barnes (London, United Kingdom)
| |
Better animal models of respiratory disease? M. Belvisi (London, United Kingdom)
| |
Alternatives to animal studies: virtual lung, human cells, in silico? A. Holmes (London, United Kingdom)
| |
Italian Presidency of the EU: health priorities M. Marletta (Rome, Italy)
| |
Revised EU directive clinical trials F. Meunier (Brussels, Belgium)
| |
National example: Italian Medicines' Agency L. Pani (Rome, Italy)
| |
Innovative Medicines Initiatives (IMI) N. Seigneuret (Brussels, Belgium)
| |
A national example: German Centre for Lung Research W. Seeger (Giessen, Germany)
| |
The Alliance for biomedical research in Europe K. Sipido (Leuven, Belgium)
| |
Regulatory aspects of respiratory drugs S. Bonini (London, United Kingdom)
| |
Benefit versus risk of innovation for industry R. Strieter (Cambridge, United States of America)
| |
Case study in cystic fibrosis: the US CF Foundation research and clinical development programmes T. Ferkol (St. Louis, United States of America)
| |
Patient's perspective I K. Hansen (Denmark)
| |
Patient's perspective II F. Buccella (Rome, Italy)
| |
Bench to bedside: what are the impediments to translational research M. Rawlins (London, United Kingdom)
| |